Key Transaction Details
- Transaction value: $250 million on a cash-free, debt-free basis inclusive of normalized working capital
- Expected closing: Before end of June 2026
- Acquired entity: Lannett Company LLC, a Pennsylvania-based generic pharmaceutical company
Strategic Rationale and Benefits
- Expands Aurobindo USA's product offering in complex, non-opioid controlled substances
- Adds U.S.-based manufacturing facility in Seymour, Indiana with annual production capacity of approximately 4 billion doses
- Strengthens domestic manufacturing footprint aligning with U.S. policy priorities for supply chain resilience
- Expected to be immediately accretive to Aurobindo Group's earnings per share
- Anticipated cost efficiencies, SG&A synergies, and operational integration advantages
- Enhances portfolio with differentiated pipeline of complex generics and controlled substances
Management Commentary
Swami S. Iyer, CEO of Aurobindo Pharma USA: Characterized the acquisition as a "highly compelling strategic and financial opportunity" that accelerates revenue growth, strengthens U.S. manufacturing capabilities, and enhances position in complex non-opioid controlled substances. Expected to deliver immediate earnings accretion and long-term value through operational synergies and pipeline expansion.
Tim Crew, CEO of Lannett Company: Expressed delight in joining forces with Aurobindo, noting that Aurobindo's market reach and resources will help make Lannett's portfolio more affordable and accessible for patients. Acknowledged the professionalism and hard work of both teams in reaching this milestone.
Company Background
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India, operating in over 150 countries with 30+ manufacturing facilities approved by major regulatory agencies including USFDA, UK MHRA, and others.
#AurobindoPharma #M&A #FTCApproval #SEBIDisclosure #StrategicAcquisition #Positive